SBI Pharma Fund (Equity, Equity Sectoral-pharma)

High
19 yrs 1 monthsStarted on:14 Jul 1999
₹ 957.96 Cras on: 13 Jul 2018
Long Term Horizon
2.26%
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.

Exit Load

Scheme Documents

Similar Funds
RELIANCE PHARMA FUND
Return (CAGR) 20.81%
Crisil Ranking NA
Value Research NA
UTI-Pharma Healthcare Fund
Return (CAGR) 13.44%
Crisil Ranking NA
Value Research NA

Tenure

TenureReturns (CAGR)
1 Month0.37

SIP Returns

TenureReturns (CAGR)
5 YR0.19
10 YR14.07

Portfolio

Company Name% Assets
Strides Shasun Ltd.8.32
Sun Pharmaceutical Inds. Ltd.8.24
Cipla Ltd.7.72
Torrent Pharmaceuticals Ltd.6.44
Aurobindo Pharma Ltd.6.34
Divi's Laboratories Ltd.5.42
Cadila Healthcare Ltd.5.2
Alkem Laboratories Ltd.4.77
Dr. Reddy's Laboratories Ltd.4.67
Biocon Ltd.4.53

Top Sectoral Holdings

Sector Name% Assets
Healthcare94.65

Indicators

LabelValue
Portfolio turnover ratio49
Standard Deviation15.49%
Beta0.7%

Tanmaya Desai

Mr. Desai is a B.E. (Electronics), MBA (Finance) and CFA (Level III).
Prior to joining SBI Mutual Fund he has worked with D.J. Sanghvi College of Engineering and Patni Computer Systems Ltd.
© CRISIL Limited 2017. All Rights Reserved